<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696368</url>
  </required_header>
  <id_info>
    <org_study_id>1808964513</org_study_id>
    <nct_id>NCT03696368</nct_id>
  </id_info>
  <brief_title>The Hoosier Moms Cohort</brief_title>
  <official_title>Understanding Diverse Contributors to Gestational Diabetes Mellitus and Its Near-to-Long Term Consequences: An Indiana University Grand Challenges Precision Health Initiative Cohort Study (The Hoosier Moms Cohort)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Hoosier Moms Cohort (HMC) study's goal is to better understand the pathophysiology
      underlying the development of gestational diabetes mellitus (GDM) in pregnant women and its
      transition to Type 2 diabetes mellitus in mothers and their exposed children.

      The HMC study wants to determine what biomarkers (genetic, blood based and
      behavioral/interventional) can be identified in pregnant women affected with GDM and how
      those biomarkers can be used to impact preventative care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Predictive GDM genetic risk models will be tested and refined in the Hoosier Moms Cohort. In
      addition to prospectively using genetic information to predict GDM risk, the Hoosier Moms
      Cohort will incorporate the use of wearable/digital devices for collection of detailed
      behavioral information, support development of novel dietary capture methods, and enable the
      collection of specimens specifically aimed at multiple 'omics' techniques to engage in a
      detailed, multidimensional assessment of pathophysiologic pathways and biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GDM Diagnosis</measure>
    <time_frame>42 weeks or less gestational age</time_frame>
    <description>Number of subjects diagnosed with GDM</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Gestational Diabetes</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Maternal blood

        -  Maternal urine

        -  Maternal stool

        -  Cord blood

        -  Infant buccal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        500 pregnant women with an enhanced risk of GDM will be recruited from obstetrical clinics
        associated with the Indiana University School of Medicine or by self referral.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton gestation

          -  Gestational age â‰¤ 20+0 confirmed via American Congress of Obstetrics and Gynecology
             (ACOG) ultrasound dating guidelines

          -  18 years old or greater at time of consent

        Exclusion Criteria:

          -  Pre pregnancy diagnosis of Type 1 Diabetes or Type 2 Diabetes or Screening Hemoglobin
             A1C that is greater than or equal to 6.5% or two abnormal values on a 3 hours Oral
             Glucose Tolerance Test (100g load) before 20 weeks gestation

          -  Pre pregnancy chronic usage of systemic steroids (inhaled and short term usage
             acceptable)

          -  Planned pregnancy termination

          -  Unable to provide informed consent in English or Spanish

          -  Major fetal anomalies as listed below that are known prior to enrollment. If these are
             discovered after enrollment, the participant may be allowed to participate, unless the
             discovered fetal anomaly is a lethal anomaly.

        Major Fetal Anomalies to be Excluded:

          -  Congenital diaphragmatic hernia

          -  Congenital cystic adenomatoid malformation

          -  Pleural effusions

          -  Chylothorax

          -  Bronchogenic cyst

          -  Bronchopulmonary sequestration

          -  Anomalous pulmonary venous return

          -  Tricuspid atresia

          -  Mitral atresia

          -  Double right ventricle

          -  Ebstein's malformation

          -  Pulmonary atresia

          -  Hypoplastic left heart syndrome

          -  Aortic coarctation

          -  Fetal arrhythmias (tachycardia or bradycardia)

          -  Transposition of the great vessels

          -  Tetrology of Fallot

          -  Double outlet right ventricle

          -  Aortic stenosis

          -  Holoprosencephaly

          -  Anencephaly

          -  Dandy-Walker malformation or variant

          -  Septo-optic dysplasia

          -  Neural tube defect

          -  Vein of Galen aneurysm

          -  Bilateral renal agenesis

          -  Cystic renal disease (polycystic or multicystic)

          -  Any genitourinary lesion accompanied by oligohydramnios at &lt;24 weeks

          -  Obstructive uropathy

          -  Horseshoe kidney

          -  Megacystis microcolon

          -  Achondrogenesis

          -  Thanatophoric dysplasia

          -  Thoracic dysplasia

          -  Osteogenesis imperfect

          -  Short rib polydactyly

          -  Any skeletal defect associated with small thorax

          -  Hypophosphatemia

          -  Any karyotypic abnormality

          -  Any suspected genetic syndrome

          -  Cleft lip/palate

          -  Micrognathia

          -  Hydrops

          -  Fetal anemia (&lt;35% on cordocentesis)

          -  Neck mass

          -  Gastroschisis

          -  Omphalocele
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Haas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Haas, MD, MS</last_name>
    <phone>317-880-3960</phone>
    <email>dahaas@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen M Flannery, BS</last_name>
    <phone>317-880-3961</phone>
    <email>kamaflan@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IU Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Flannery, BS</last_name>
      <phone>317-880-3961</phone>
      <email>kamaflan@iu.edu</email>
    </contact>
    <investigator>
      <last_name>David M Haas, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUH Coleman Center for Women</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen M Flannery</last_name>
      <phone>317-880-3961</phone>
      <email>kamaflan@iu.edu</email>
    </contact>
    <investigator>
      <last_name>David M Haas, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUH Prenatal Diagnosis Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen M Flannery</last_name>
      <phone>317-880-3961</phone>
      <email>kamaflan@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney and Lois Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Flannery, BS</last_name>
      <phone>317-880-3961</phone>
      <email>kamaflan@iu.edu</email>
    </contact>
    <investigator>
      <last_name>David M Haas, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

